Viking, General Atlantic lead $80m round for Pharvaris

Also participating in the round wee Foresite Capital, Bain Capital Life Sciences, VenBio Partners and Venrock Healthcare Capital Partners.

Pharvaris intends to use the funding to advance its drug candidate PHVS416. The company expects to launch RapidE-1, a multi-centre phase-II placebo-controlled on-demand study of PHVS416 in HAE patients, in 2021.

Previous funding
Life Sciences Partners (LSP), Idinvest and Kurma Partners backed a series-A round for Pharvaris in 2016.

In September 2019, Pharvaris raised a $66m funding round backed by Foresite, Bain Capital Life Sciences, VenBio, and Venrock, as well as existing investors, LSP, Kurma and Idinvest.

Company
Pharvaris focuses on the development of oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE), a genetic condition that causes unpredictable and often painful swelling of areas of the body, including the extremities, the gastrointestinal tract and airways. Its therapies can also be used to treat other bradykinin-B2-receptor-mediated indications.

The company was founded in 2015 and has 21 employees, according to LinkedIn. Pharvaris is based in Zug and has an additional presence in Leiden in the Netherlands.

People
Pharvaris – Berndt Modig (co-founder, CEO).
General Atlantic – Brett Zbar (managing director, head of life sciences).
VenBio Partners – Richard Gaster (partner).
Bain Capital Life Sciences – Ricky Sun (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Venture
• Switzerland
• General Atlantic
• Viking Venture A/S